Crossmark

New respiratory syncytial virus immunization products in low- and middle-income countries: potential for cost-effective impact on a high burden of disease in young infants

Crossref DOI link: https://doi.org/10.1186/s12916-023-02883-x

Published Online: 2023-05-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Srikantiah, Padmini

Klugman, Keith P.
Funding

Funding for this research was provided by:

Bill and Melinda Gates Foundation
License Information

Text and Data Mining valid from 2023-05-15

Version of Record valid from 2023-05-15
More Information

Article History

Received: 10 March 2023

Accepted: 27 April 2023

First Online: 15 May 2023

Declarations

:

: Not applicable.

: Not applicable.

: The authors declare that they have no competing interests.

Document is current

Any future updates will be listed below